Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | PAM | P19021 | 1/20 | 0.50 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2770961 | 1.00 | KDM4E (0.55) | KDM4ERAB9AALDH1A1IDO1MAOB | |
| SCHEMBL14275030 | 0.91 | KDM4E (0.52) | KDM4ERAB9AALDH1A1IDO1MAOB | |
| SCHEMBL11597360 | 0.91 | PRMT1 (0.55) | KDM4ERAB9AALDH1A1IDO1MAOB | |
| SCHEMBL11597357 | 0.91 | PRMT1 (0.55) | KDM4ERAB9AALDH1A1IDO1MAOB | |
| SCHEMBL3884865 | 0.89 | RAB9A (0.47) | KDM4ERAB9AALDH1A1IDO1MAOB | |
| SCHEMBL3884868 | 0.89 | RAB9A (0.47) | KDM4ERAB9AALDH1A1IDO1MAOB | |
| SCHEMBL2189374 | 0.87 | RAB9A (0.53) | KDM4ERAB9AALDH1A1IDO1MAOB | |
| SCHEMBL4356479 | 0.87 | RAB9A (0.49) | KDM4ERAB9AALDH1A1IDO1MAOB | |
| SCHEMBL4356484 | 0.87 | RAB9A (0.49) | KDM4ERAB9AALDH1A1IDO1MAOB | |
| SCHEMBL2189373 | 0.87 | RAB9A (0.53) | KDM4ERAB9AALDH1A1IDO1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8308892-B2 | Di-cinnamyl compounds and methods for use thereof | DESIGNER MOLECULES, INC. (US) | 2012-11-13 | — | — | US | claimed |
| US-20090288768-A1 | DI-CINNAMYL COMPOUNDS AND METHODS FOR USE THEREOF | DESIGNER MOLECULES, INC. | 2009-11-26 | — | — | US | claimed |
| US-12317892-B2 | Micro and nanoparticulate compositions comprising anti-microbially active groups | NOBIO LTD. (IL) | 2025-06-03 | — | — | US | disclosed |
| EP-3675801-B1 | ANTI-MICROBIAL PARTICLES AND METHODS OF USE THEREOF | NOBIO LTD (IL) | 2024-01-24 | — | — | EP | disclosed |
| CN-111093595-B | Compositions and medical devices comprising antimicrobial particles | 诺比奥有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20220225612-A1 | MICRO AND NANOPARTICULATE COMPOSITIONS COMPRISING ANTI-MICROBIALLY ACTIVE GROUPS | NOBIO LTD. (IL) | 2022-07-21 | — | — | US | disclosed |
| US-20220142155-A1 | ANTI-MICROBIAL PARTICLES AND METHODS OF USE THEREOF | NOBIO LTD. (IL) | 2022-05-12 | — | — | US | disclosed |
| US-20220046915-A1 | COMPOSITIONS AND MEDICAL DEVICES COMPRISING ANTI-MICROBIAL PARTICLES | NOBIO LTD. (IL) | 2022-02-17 | — | — | US | disclosed |
| US-11178867-B2 | Micro and nanoparticulate compositions comprising anti-microbially active groups | NOBIO LTD. (IL) | 2021-11-23 | — | — | US | disclosed |
| US-11134676-B2 | Anti-microbial particles and methods of use thereof | NOBIO LTD. (IL) | 2021-10-05 | — | — | US | disclosed |
| EP-3675802-A1 | COMPOSITIONS AND MEDICAL DEVICES COMPRISING ANTI-MICROBIAL PARTICLES | Nobio Ltd. (IL) | 2020-07-08 | — | — | EP | disclosed |
| US-8308892-B2 | Di-cinnamyl compounds and methods for use thereof | DESIGNER MOLECULES, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| EP-1967509-B1 | METHOD FOR PRODUCING PRIMARY AMINE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-7652170-B2 | Method for producing primary amine compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20090288768-A1 | DI-CINNAMYL COMPOUNDS AND METHODS FOR USE THEREOF | DESIGNER MOLECULES, INC. | 2009-11-26 | — | — | US | disclosed |
| US-20090287023-A1 | METHOD FOR PRODUCING PRIMARY AMINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-1967509-A1 | METHOD FOR PRODUCING PRIMARY AMINE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-09-10 | — | — | EP | disclosed |
| EP-0497202-B1 | Polyamine thiols as radioprotective agents | MERRELL DOW PHARMA (US) | 1995-09-13 | — | — | EP | disclosed |
| US-5217964-A | POLYAMINE THIOLS AS RADIOPROTECTIVE AGENTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-06-08 | — | — | US | disclosed |
| EP-0497202-A1 | Polyamine thiols as radioprotective agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142155-A1 | ANTI-MICROBIAL PARTICLES AND METHODS OF USE THEREOF | LPO, MPO, CAPG | KDM4E 4003/4885RAB9A 2470/4885ALDH1A1 3866/4885 |
| US-11178867-B2 | Micro and nanoparticulate compositions comprising anti-microbially active groups | MPO, LPO, DSTN | KDM4E 3729/4885RAB9A 593/4885ALDH1A1 3608/4885 |
| US-12317892-B2 | Micro and nanoparticulate compositions comprising anti-microbially active groups | MPO, LPO, DSTN | KDM4E 3729/4885RAB9A 593/4885ALDH1A1 3608/4885 |
| US-20220225612-A1 | MICRO AND NANOPARTICULATE COMPOSITIONS COMPRISING ANTI-MICROBIALLY ACTIVE GROUPS | MPO, LPO, DSTN | KDM4E 3729/4885RAB9A 593/4885ALDH1A1 3608/4885 |
| US-11134676-B2 | Anti-microbial particles and methods of use thereof | LPO, MPO, CAPG | KDM4E 4003/4885RAB9A 2470/4885ALDH1A1 3866/4885 |
| US-20090287023-A1 | METHOD FOR PRODUCING PRIMARY AMINE COMPOUND | HRH3, HRH4, C5 | KDM4E 3624/4885RAB9A 2569/4885ALDH1A1 374/4885 |
| US-20220046915-A1 | COMPOSITIONS AND MEDICAL DEVICES COMPRISING ANTI-MICROBIAL PARTICLES | CAPG, CD47, CUTA | KDM4E 4045/4885RAB9A 2647/4885ALDH1A1 4597/4885 |
| US-20090288768-A1 | DI-CINNAMYL COMPOUNDS AND METHODS FOR USE THEREOF | CAD, DBF4, ACMSD | KDM4E 131/4885RAB9A 4033/4885ALDH1A1 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.